ARS Pharmaceuticals, Inc.
SPRY
$13.77
-$0.87-5.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 361.05% | -52.83% | -21.61% | -43.58% | 51.78% |
| Total Depreciation and Amortization | 38.10% | 16.67% | 63.64% | -8.33% | -42.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54.05% | 20.81% | 9.44% | 142.29% | -47.47% |
| Change in Net Operating Assets | -471.41% | -23.50% | 68.07% | 120.70% | -1,145.50% |
| Cash from Operations | 390.34% | -98.75% | -8.48% | 61.45% | -36.37% |
| Capital Expenditure | -115.71% | -268.42% | 54.22% | -191.21% | 311.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -698.29% | 234.50% | -49.56% | -132.49% | 155.68% |
| Cash from Investing | -705.07% | 232.99% | -48.55% | -132.69% | 155.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 125.44% | 24.77% | 111.24% | -85.71% | 95.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10,328.82% | 24.77% | 111.24% | -85.71% | 95.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 268.20% | 115.64% | -29.50% | -243.36% | 117.85% |